Uncategorized
VIDEO: LADDER trial underway to compare long-term port delivery of ranibizumab with monthly injections
SEATTLE — At the Association for Research in Vision and Ophthalmology meeting, Jill Hopkins, MD, medical director at Genentech, describes the company's LADDER trial, an ongoing phase 2 trial whose purpose is to compare monthly intravitreal injections of ranibizumab in patients with wet age-related macular degeneration with long-term delivery of ranibizumab delivered via the company's port delivery system.